Clinical Study to Compare Dental Plaque Control

• Status: Completed
• Trial end date: 2007-11-01
• Target enrollment: 0
• Participant gender: All

Summary

This clinical study was to evaluate the control of dental plaque formation after toothbrushing for 4 days with each of the 4 study toothpastes.

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Colgate Palmolive
• Treatments: Fluorides; Fluorophosphate; Listerine; Sodium Fluoride; Triclosan

Criteria

Inclusion Criteria:

• Male or female volunteers at least 18 - 53 years of age

• Good general health

• Must sign informed consent form

• Minimum of 20 natural uncrowned teeth (excluding third molars) must be present.

• No history of allergy to personal care consumer products, or their ingredients, relevant to any ingredient in the test products as determined by the dental/medical professional monitoring the study.

Exclusion Criteria:

• Subjects unable or unwilling to sign the informed consent form.

• Medical condition which requires pre-medication prior to dental visits/procedures

• Moderate or advanced periodontal disease or heavy dental tartar (calculus).

• 2 or more decayed untreated dental sites at screening.

• Other disease of the hard or soft oral tissues.

• Impaired salivary function (e.g. Sjogren's syndrome or head and neck irradiation).

• Use of medications that are currently affecting salivary function

• Use of antibiotics or antimicrobial drugs within 30 days prior to study visit #1.

• Pregnant or nursing women.

• Participation in any other clinical study within 1 week prior to enrollment into this study.

• Use of tobacco products

• Subjects who must receive dental treatment during the study dates.

• Current use of Antibiotics for any purpose.

• Presence of an orthodontic appliance which interferes with plaque scoring.

• History of allergy to common dentifrice ingredients.

• History of allergy to arginine (amino acid)

• History of allergy to bicarbonate

• Immune compromised individuals (HIV, AIDS, immuno suppressive drug therapy)